News | Stents Drug Eluting | September 30, 2019

Resolute Onyx Drug-Eluting Stent Noninferior to Polymer-Free Drug-Coated Stent With One-Month DAPT

Results from the Onyx ONE Study reported at TCT 2019

Resolute Onyx Drug-Eluting Stent Noninferior to Polymer-Free Drug-Coated Stent With One-Month DAPT

September 30, 2019 – The first randomized trial to compare a durable polymer drug-eluting stent to a polymer-free drug-coated stent in patients at high risk of bleeding and treated with one-month dual antiplatelet therapy (DAPT) found that both are clinically safe and effective.

Findings from the Onyx ONE trial were reported at the 31st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, Sept. 25-29 in San Francisco, sponsored by the Cardiovascular Research Foundation (CRF).

Up to 40 percent of patients undergoing percutaneous coronary intervention (PCI) have high bleeding risk (HBR) characteristics, and current guidelines recommend three to six months of DAPT for HBR patients undergoing PCI, with consideration for DAPT duration as short as one month in selected patients. However, there are scant randomized data with shorter durations of DAPT, especially for current-generation polymer-based DES. The Onyx ONE trial compared a polymer-based DES compared to polymer-free drug-coated stents (DCS) in HBR patients treated with one-month DAPT (aspirin and an oral P2Y12 inhibitor).

The prospective, multicenter, single-blind randomized trial enrolled 2,000 HBR patients who were randomized 1:1 at 84 global sites. The primary safety endpoint was cardiac death, myocardial infarction (MI) or definite/probable stent thrombosis at one year. The powered secondary endpoint was target lesion failure, a composite of cardiac death, target vessel myocardial infarction or clinically driven target lesion revascularization. Other secondary endpoints included device and procedure success rates, Bleeding Academic Research Consortium (BARC) bleeding, and the individual components of the primary endpoints.

Of the 1,996 patients randomized, one-year follow-up was available in 98.5 percent (n=988) of the ZES arm and 97.6 percent (n=969) of the DCS arm. Baseline and lesion characteristics were similar among both groups. Crossover to an alternative stent occurred more frequently in the DCS arm (40 vs. 2, p<0.001), and ZES showed improved angiographic outcomes resulting in greater device success post-PCI (92.8 percent for ZES and 89.7 percent for DCS, p=0.007). At two months after PCI, 92 percent of patients were on single antiplatelet therapy and 88 percent were at one year. The primary safety endpoint of cardiac death, MI or definite/probable stent thrombosis at one year was 17.1 percent for ZES and 16.9 percent for DCS (Pnon-inferiority = 0.011). In addition, the powered secondary effectiveness endpoint of TLF at one year was 18 percent for ZES and 17.9 percent for DCS (HR 1.02, 95 percent CI [0.83, 1.26], p=0.84). Bleeding rates were also similar among both treatment groups.

“The Onyx ONE global randomized trial is the first study to evaluate outcomes between a polymer-based DES and a polymer-free DCS with one-month DAPT after PCI in a complex patient population,” said Stephan Windecker, M.D., director and chief physician, Department of Cardiology at the Swiss Cardiovascular Center in Bern, Switzerland. “The data shows that the polymer-based zotarolimus-eluting stent is as safe and effective as the polymer-free drug-coated stent in HBR patients treated with one- month DAPT and provides important evidence to inform clinical decision-making for high bleeding risk patients.”

The Onyx ONE study was funded by Medtronic. Windecker disclosed research grants to the institution from Abbott, Amgen, Bayer, Bristol Myers-Squibb, Boston Scientific, Biotronik, CLS Behring, Edwards Lifesciences, Medtronic, Polares and Sinomed.

More late-breaking coverage of TCT 2019

For more information: www.crf.org/tct

Related Content

Videos | Antiplatelet and Anticoagulation Therapies | October 11, 2019
Ajay J. Kirtane, M.D., associate professor of medicine at Columbia University Irving Medical Center and director of the...
Videos | Antiplatelet and Anticoagulation Therapies | October 08, 2019
American Heart Association President Robert Harrington, M.D., explains the reasons for shorter duration dual-...
Three-Month DAPT Post-PCI Demonstrates Low Adverse Event Rate in High-Bleeding Risk Patients
News | Antiplatelet and Anticoagulation Therapies | September 30, 2019
Data from the EVOLVE Short DAPT study found that shortened three-month dual antiplatelet therapy (DAPT) did not...
Brilinta Monotherapy Reduces Clinically Relevant Bleeding Risk Post-PCI in High-Risk Patients
News | Antiplatelet and Anticoagulation Therapies | September 26, 2019
New data from the Phase IV independent TWILIGHT trial showed Brilinta (ticagrelor) monotherapy reduced the risk of BARC...
Aspirin Should Not Be Recommended for Healthy People Over 70
News | Antiplatelet and Anticoagulation Therapies | September 20, 2019
Low-dose aspirin does not prolong disability-free survival of healthy people over 70, even in those at the highest risk...
Ticagrelor Plus Aspirin Reduces Ischemic Events in Stable Coronary Patients With Diabetes
News | Antiplatelet and Anticoagulation Therapies | September 10, 2019
The combination of ticagrelor and aspirin reduces ischemic events compared with aspirin alone in patients with stable...
Prasugrel Cuts Ischemic Events in Acute Coronary Syndrome Patients
News | Antiplatelet and Anticoagulation Therapies | September 09, 2019
Prasugrel is superior to ticagrelor for reducing ischemic events in patients with acute coronary syndrome and a planned...
Advances in Anticoagulants Expand Options for VTE Prevention, Treatment
News | Antiplatelet and Anticoagulation Therapies | July 26, 2019
A new article published in AACN Advanced Critical Care outlines the traditional anticoagulant therapies familiar to...
Overlay Init